Last reviewed · How we verify

NCT07152834: AATD-SAO

Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway Obstruction

Recruiting now Last updated 10 September 2025
What this trial tests

trial testing Blood Sampling in Alpha 1-antitrypsin Deficiency (AATD) in 734 participants. Currently enrolling.

Timeline
6 August 2025
Primary endpoint
30 December 2025
5 January 2026

Quick facts

Lead sponsorMuğla Sıtkı Koçman University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment734
Start date6 August 2025
Primary completion30 December 2025
Estimated completion5 January 2026
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Muğla Sıtkı Koçman University

Who can join

18 and older, any sex, with Alpha 1-antitrypsin Deficiency (AATD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Brief Summary: This study aims to find out if a genetic condition called Alpha-1 Antitrypsin Deficiency (AATD) is more common in people who have shortness of breath and signs of airway obstruction on their breathing tests. Alpha-1 antitrypsin (AAT) is a protein that protects the lungs from damage. AATD is an inherited condition where the body does not make enough of this protein, which can lead to lung diseases like emphysema, especially in smokers. Investigators hypothesize that low AAT levels or related genetic mutations may be a contributing factor to airway obstruction in patients complaining of shortness of breath. To test this, investigators will recruit patients from our outpatient clinic who are being evaluated for shortness of breath and are having a standard breathing test (spirometry). Investigators will measure their AAT levels and test for the most common genetic mutations that cause AATD using a small blood sample. Investigators will then compare the AAT levels and genetic results between different groups of patients, such as smokers and non-smokers with and without airway obstruction. Investigators will also see if the severity of a patient's shortness of breath is related to their AAT levels. The goal is to improve the detection of AATD in this patient population, which could lead to better diagnoses and specific treatments for those who have this condition.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood Sampling

Trials testing the same drug.

Other Muğla Sıtkı Koçman University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07152834.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing